The C‐Terminal Domain of Chondroadherin: A New Regulator of Osteoclast Motility Counteracting Bone Loss. (August 2014)

• Record Type: Journal Article
• Authors: Capulli, Mattia; Olstad, Ole K; Önnerfjord, Patrik; Tillgren, Viveka; Muraca, Maurizio; Gautvik, Kaare M; Heinegård, Dick; Rucci, Nadia; Teti, Anna
• Is Part Of: Journal of bone and mineral research. Volume 29:Number 8(2014:Aug.)
• Page Start: 1833
• Page End: 1846
• Publication Date: 2014-08
• Subjects: Bones -- Metabolism -- Periodicals; Mineral metabolism -- Periodicals; 612.392
• DOI: 10.1002/jbmr.2206
• Languages: English
• ISSNs: 0884-0431

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>ABSTRACT</title> <sec id="jbmr2206-sec-0001" sec-type="section"> <p>Chondroadherin (CHAD) is a leucine‐rich protein promoting cell attachment through binding to integrin α<sub>2</sub>β<sub>1</sub> and syndecans. We observed that CHAD mRNA and protein were lower in bone biopsies of 50‐year‐old to 65‐year‐old osteoporotic women and in bone samples of ovariectomized mice versus gender/age–matched controls, suggesting a role in bone metabolism. By the means of an internal cyclic peptide (cyclicCHAD), we observed that its integrin binding sequence impaired preosteoclast migration through a nitric oxide synthase 2–dependent mechanism, decreasing osteoclastogenesis and bone resorption in a concentration‐dependent fashion, whereas it had no effect on osteoblasts. Consistently, cyclicCHAD reduced transcription of two nitric oxide downstream genes, <italic>migfilin</italic> and <italic>vasp</italic>, involved in cell motility. Furthermore, the nitric oxide donor, S‐nitroso‐N‐acetyl‐D, L‐penicillamine, stimulated preosteoclast migration and prevented the inhibitory effect of cyclicCHAD. Conversely, the nitric oxide synthase 2 (NOS2) inhibitor, N5‐(1‐iminoethyl)‐l‐ornithine, decreased both preosteoclast migration and differentiation, confirming a role of the nitric oxide pathway in the mechanism of action triggered by cyclicCHAD. In vivo, administration of cyclicCHAD was well tolerated and increased bone volume in healthy mice, with no adverse effect. In ovariectomized mice cyclicCHAD improved bone mass by both a preventive and a curative treatment protocol, with an effect in line with that of the bisphosphonate alendronate, that was mimicked by the NOS2 inhibitor [L‐N6‐(1‐Iminoethyl)‐lysine.2 dihydrochloride]. In both mouse models, cyclicCHAD reduced osteoclast and bone resorption without affecting osteoblast parameters and bone formation. In conclusion, CHAD is a novel regulator of bone metabolism that, through its integrin binding domain, inhibits preosteoclast motility and bone resorption, with a potential translational impact for the treatment of osteoporosis. © 2014 American Society for Bone and Mineral Research.</p> </sec> </abstract>